[어바웃 G] 삼성에피스홀딩스 CFO, 사내이사 눈앞…신약社 전환 변수

Samsung Bioepis Holdings is transitioning into a specialized new drug development company. The appointment of Kim Hyung-joon, the current Chief Financial Officer (CFO), as an inside director is drawing attention as it may lead to changes in the company's capital allocation structure. Kim's role as an executive director will allow him to directly participate in investment approval processes, which could lead to more quantitative decision-making regarding R&D spending and prioritization as the company focuses on expanding its new drug pipeline while maintaining its biosimilar business.